Blog

For the 2nd year in a row, the Drug Science team was invited to host a discussion around psychedelics at We Out Here Festival, which is held in Wimborne St Giles, Dorset.

Drug Science responded to the Advisory Council on the Misuse of Drugs’ (ACMD’s) call on Ketamine use, harms and interventions. We hope that our evidence can help to develop rational debate, policy making and scheduling about Ketamine.

Germany has recently taken a landmark step by introducing compassionate access to psilocybin for patients with treatment-resistant depression (TRD), marking the first such programme in the European Union.

Despite the resurgence of research into the clinical efficacy and mechanism of action of psychedelic drugs such as such as psilocybin, LSD, DMT, and MDMA they are currently in Schedule 1 of the Misuse of Drugs regulations 2001.

Last week, the Ministry of Health quietly marked a historic milestone: it granted a license to Christchurch-based psychiatrist Professor Cameron Lacey to prescribe psilocybin for treatment-resistant depression. This is the first time the psychedelic compound will be legally prescribed in New Zealand outside of a clinical trial.

The reemergence of psychedelic therapy presents a rare opportunity to reimagine psychiatry’s epistemic foundations. Rather than simply repackaging these substances within a biomedical framework, this moment should prompt critical interrogation of the assumptions underlying dominant models of mental illness and healing.

Current regulation frameworks for medicines struggle to address the combination of pharmacological and psychotherapeutic elements in psychedelic therapy.

The CPRG officially marked its launch by hosting the 1st Cambridge Psychedelic Research Day on March 12, 2025 at Clare College, the University of Cambridge’s second-oldest college, founded in 1326.

As our societies grapple with environmental and mental health challenges, investigating potential avenues for restoring relations with nature is more important than ever.

The global regulatory landscape for psilocybin and PSILO-AT remains highly variable, with significant differences in the scope and clarity of medical governance.

Although there is growing support for the protective effects of psychedelics on mental health, recent evidence finds racial and ethnic minorities gain fewer benefits.

The increasing incidence of opioid dependence linked to the consumption of unwashed poppy seeds (UPSs) is an emerging public health concern.

Last week, the Ukrainian Ministry of Health took an important step toward enabling scientific research with psychedelics.

When the email invite came I thought it was a hoax so I contacted Wolf Singer – another neuroscientist. He reassured me it was for real, an

The past 50 years have seen remarkable advances in the science of medicine. The pharmacological treatments of disorders such as hypertension

Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds potential for transforming psychiatry and

Minorities’ diminished psychedelic returns: Cardio-metabolic health. Race differences remain a critically understudied gap in psychedelic li